Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...
Despite a flurry of actions this week to extend AI leadership, the administration is dismantling the very advantages that established America’s global lead in AI in the first place. This story is part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results